{"id":"lactobacillus-plantarum-strain-299","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Bacteremia (rare, in immunocompromised patients)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This live biotherapeutic product colonizes the gastrointestinal tract and produces metabolites that strengthen the intestinal epithelial barrier, reduce pathogenic bacterial translocation, and promote regulatory T cell differentiation. By restoring eubiotic conditions and enhancing mucosal immunity, it may reduce treatment-related toxicities and support immune recovery in cancer patients undergoing chemotherapy or hematopoietic stem cell transplantation.","oneSentence":"Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:13.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention or mitigation of chemotherapy-induced gastrointestinal toxicity in pediatric cancer patients"},{"name":"Support of immune recovery and reduction of infection risk in hematopoietic stem cell transplant recipients"}]},"trialDetails":[{"nctId":"NCT03057054","phase":"PHASE3","title":"Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-04-30","conditions":"Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DSM 6595","LACTOBACILLUS PLANTARUM 299"],"phase":"phase_3","status":"active","brandName":"Lactobacillus plantarum strain 299","genericName":"Lactobacillus plantarum strain 299","companyName":"Children's Oncology Group","companyId":"children-s-oncology-group","modality":"Biologic","firstApprovalDate":"","aiSummary":"Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis. Used for Prevention or mitigation of chemotherapy-induced gastrointestinal toxicity in pediatric cancer patients, Support of immune recovery and reduction of infection risk in hematopoietic stem cell transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}